$KPTI News

Karyopharm Therapeutics Extends Forbearance Period End Date To November 1, 2026

Karyopharm Therapeutics Extends Forbearance Period To October 15

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Signs Forbearance Agreement, Limited Waiver To Indentures For Additional Time To Advance Its Myelofibrosis Program; Did Not Pay $15.8M Due Under Sept. 10 Credit Agreement

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis

Karyopharm Therapeutics Submits sNDA To FDA Seeking Accelerated Approval For XPOVIO In Combination With Ruxolitinib For Patients With Myelofibrosis

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ...

Karyopharm Therapeutics Inc. (KPTI) Q2 2026 Earnings Call Transcript

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

Karyopharm Therapeutics Inc. 2026 Q2 - Results - Earnings Call Presentation

Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript

Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M Est

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)